Exposure to rizatriptan during pregnancy: Post-marketing experience up to 30 June 2004

Cephalalgia

Volumn 25, Issue 9, 2005, Pages 685-688

  Fiore, Maryellen ^a,b   Shields, K E ^a   Santanello, N ^b   Goldberg, M R ^a  

^a Clinical Risk Management and Safety Surveillance   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Exposure; Pregnancy; Rizatriptan

Indexed keywords

RIZATRIPTAN;

AMNIOCENTESIS; ARTICLE; BIRTH DEFECT; CHROMOSOME DUPLICATION; CLINICAL ARTICLE; CONGENITAL MALFORMATION; DRUG SURVEILLANCE PROGRAM; FEMALE; FETUS DEATH; HUMAN; PREGNANCY; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; QUESTIONNAIRE; REGISTER; SPONTANEOUS ABORTION; SYNDACTYLY; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; FEMALE; HUMANS; PREGNANCY; PREGNANCY OUTCOME; REGISTRIES; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 23944484687     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00929.x     Document Type: Article

References (13)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41:646-57.
2. Wainscott G, Volans GN. The outcome of pregnancy in women suffering from migraine. Postgrad Med J 1978; 54:98-102.
3. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to Sumatriptan. Headache 2001; 41:351-6.
4. Shuhaiber S, Pastuszak A, Schick B, Matsui D, Sppivey G, Brochu J, et al. Pregnancy outcome following first trimester exposure to sumatriptan. Am Acad Neurol 1998; 51:581-3.
5. O'Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263:7-12.
6. Pfaffenrath V, Rehm M. Migraine in pregnancy. What are the safest treatment options? Drug Safety 1998; 19:383-8.
7. Samra O, Forouzan I. Migraine treatment in pregnancy. Primary care update. Obstet Gynecol 2002; 9:1-6.
8. Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings E. Evidence - based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42:8-15.
9. Loder E. Safety of sumatriptan in pregnancy. CNS Drugs 2003; 17:1-7.
10. Shields KE, Wiholm BE, Hostelley LS, Striano LF, Arena SR, Sharrar RG. Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program. Drug Safety 2004; 27:1-15.
11. Paulozzi L. Metropolitan Atlanta Congenital Defects Program: Surveillance Procedure Manual and Guide to Computerized Anomaly Record. Atlanta: Centers for Disease Control and Prevention, 1998.
12. Centre for Epidemiology, Swedish Medical Birth Registry 2004 'Delivery outcome after drug exposure. July 1995 through February 2004'. Stockholm: The National Board of Health and Welfare.
13. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60:356-64.